A5082498438- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- RNA modifications and cancer
- Circular RNAs in diseases
- Ovarian cancer diagnosis and treatment
- RNA Research and Splicing
- Extracellular vesicles in disease
- Cancer, Lipids, and Metabolism
- Epigenetics and DNA Methylation
- Kruppel-like factors research
- Cancer, Hypoxia, and Metabolism
- RNA Interference and Gene Delivery
- Cancer Mechanisms and Therapy
- Signaling Pathways in Disease
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer-related gene regulation
- Genetic factors in colorectal cancer
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Ferroptosis and cancer prognosis
- PI3K/AKT/mTOR signaling in cancer
- Protein Degradation and Inhibitors
- Immune cells in cancer
- Cancer Genomics and Diagnostics
The University of Texas MD Anderson Cancer Center
2016-2025
Caris Life Sciences (United States)
2024-2025
University of Belgrade
2025
Indiana University School of Medicine
2015-2023
Namazi Hospital
2023
Eskenazi Health Foundation
2018-2023
Indiana University
2023
Indiana University – Purdue University Indianapolis
2014-2022
Spitalul Clinic Județean de Urgență Cluj-Napoca
2022
Cancer Clinic
2019
Although clinical studies have shown promise for targeting PD1/PDL1 signaling in non–small cell lung cancer (NSCLC), the regulation of PDL1 expression is poorly understood. Here, we show that regulated by p53 via miR-34. wild-type and p53-deficient lines (p53–/– p53+/+ HCT116, p53-inducible H1299, p53-knockdown H460) were used to determine if regulates miR-34a analyzed samples from patients with NSCLC mutated vs tumors The Cancer Genome Atlas Lung Adenocarcinoma (TCGA LUAD). We confirmed a...
The functional roles of SNPs within the 8q24 gene desert in cancer phenotype are not yet well understood. Here, we report that CCAT2 , a novel long noncoding RNA transcript (lncRNA) encompassing rs6983267 SNP, is highly overexpressed microsatellite-stable colorectal and promotes tumor growth, metastasis, chromosomal instability. We demonstrate MYC miR–17–5p, miR–20a up-regulated by through TCF7L2-mediated transcriptional regulation. further identify physical interaction between TCF7L2...
Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, phase 2 trials are ongoing glioblastoma (GBM). Previous reports have suggested that responses more frequent patients with tumors express PD-L1; however, this been disputed. At issue is validation PD-L1 biomarker assays prognostic impact. Using immunohistochemical analysis, we measured incidence expression 94 GBM. We...
Background and Purpose— Identification of risk factors for dementia after stroke is best performed in comparison with stroke-free controls, because older subjects at high also have a substantial the absence stroke. Previous case-control studies were hospital-based. We used nested design to prospectively evaluate these community-based Framingham Study cohort. Methods— compared 212 who free January 1982 sustained first this date, 1060 age- sex-matched, stroke- dementia-free controls....
How exosomic microRNAs (miRNAs) contribute to the development of drug resistance in context tumor microenvironment has not been previously described neuroblastoma (NBL). Coculture experiments were performed assess transfer miR-21 from NBL cells human monocytes and miR-155 cells. Luciferase reporter assays targeting TERF1 Tumor growth was measured xenografts treated with Cisplatin peritumoral (n = 6 mice per group) CD163, miR-155, levels assessed 20 primary tissues by Human Exon Arrays...
MicroRNAs (miRNAs) are small RNA molecules that regulate gene expression at the posttranscriptional level and critical for many cellular pathways. The disruption of miRNAs their processing machineries also contributes to development human tumors. A common scenario miRNA in carcinogenesis is emerging shows impaired production and/or down-regulation these transcripts occurs neoplasms. Several lost have tumor-suppressor features, so strategies restore globally malignancies would be a welcome...
Thrombocytosis is present in more than 30% of patients with solid malignancies and correlates worsened patient survival. Tumor cell interaction various cellular components the tumor microenvironment including platelets crucial for growth metastasis. Although it known that can infiltrate into tissue, secrete pro-angiogenic pro-tumorigenic factors thereby increase growth, precise molecular interactions between metastatic cancer cells are not well understood. Here we demonstrate induce...
BackgroundCirculating miRNAs are known to play important roles in intercellular communication. However, the effects of exosomal on cells not fully understood.MethodsTo investigate role miR-1246 ovarian cancer (OC) microenvironment, we performed RPPA as well many other vitro functional assays (sensitive; HeyA8, Skov3ip1, A2780 and chemoresistant; HeyA8-MDR, Skov3-TR, A2780-CP20). Therapeutic effect inhibitor treatment was tested OC animal model. We showed uptake macrophages by co-culture...
We describe a role for the complement system in enhancing cancer growth. Cancer cells secrete proteins that stimulate tumor growth upon activation. Complement promotes via direct autocrine effect is partially independent of tumor-infiltrating cytotoxic T cells. Activated C5aR and C3aR signal through PI3K/AKT pathway cells, silencing PI3K or AKT gene eliminates progrowth effects stimulation. In patients with ovarian lung cancer, higher tumoral C3 mRNA levels were associated decreased overall...
The standard treatment for high-grade serous ovarian cancer is primary debulking surgery followed by chemotherapy. extent of metastasis and invasive potential lesions can influence the outcome these surgeries. Here, we explored underlying mechanisms that could increase metastatic in cancer. We discovered FABP4 (fatty acid binding protein) substantially cells. also found miR-409-3p regulates cells hypoxia decreases levels. Treatment with DOPC nanoliposomes containing either mimic or siRNA...
Antibody therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule 4 (CTLA-4) and programmed cell death 1 (PD-1) has demonstrated marked tumor regression in clinical trials. MicroRNAs (miRNAs) can modulate multiple gene transcripts including possibly more than one checkpoint could be exploited as therapeutics. Using online miRNA prediction algorithms, we searched for miRNAs that were predicted to target both PD-1 CTLA-4. MiR-138 emerged a leading candidate....
We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the mechanisms are not well understood.We characterized biologic response of taxane-resistant and taxane-sensitive models a novel FAK inhibitor (VS-6063). used reverse-phase protein arrays (RPPA) identify downstream targets in cell lines. Furthermore, we correlated clinical pathological data with nuclear cytoplasmic expression YB-1 105 samples. Statistical tests were two-sided, P values...
The clinical outcome of BC patients receiving the same treatment is known to vary considerably and thus, there a compelling need identify novel biomarkers that can select would benefit most from given therapy predict outcome. aim this study was determine prognostic value CCAT2, long ncRNA recently characterized by our group overlapping SNP rs6983267, in patients. We first evaluated RT-qPCR ISH expression CCAT2 normal breast tissue further analyzed an independent set 997 primary with regard...
miRNAs (miR) are a critical class of small (21-25 nucleotides) noncoding endogenous RNAs implicated in gene expression regulation. We identified miR-23b and miR-27b as that highly upregulated human breast cancer. found engineered knockdown substantially repressed cancer growth. Nischarin (NISCH) was augmented by well miR-27b. Notably, these were inversely expressed cancers, underscoring their biologic relevance. showed the clinical relevance high correlates with poor outcome Moreover,...
Chemotherapy for patients with metastatic colorectal cancer (CRC) is the standard of care, but ultimately nearly all develop drug resistance. Understanding mechanisms that lead to resistance individual chemotherapeutic agents may help identify novel targets and drugs will, in turn, improve therapy. Oxaliplatin a common component combination therapeutic regimen use CRC, also used as adjuvant therapy at risk recurrent disease. In this study, unbiased microRNA array screening revealed miR‐203...